Edition:
India

Corvus Pharmaceuticals Inc (CRVS.OQ)

CRVS.OQ on NASDAQ Stock Exchange Global Market

3.33USD
16 Oct 2019
Change (% chg)

-- (--)
Prev Close
$3.33
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
61,000
52-wk High
$8.89
52-wk Low
$2.53

Latest Key Developments (Source: Significant Developments)

Corvus Pharmaceuticals Posts Q2 Loss Per Share Of $0.44
Friday, 2 Aug 2019 

Aug 1 (Reuters) - Corvus Pharmaceuticals Inc ::CORVUS PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.QTRLY LOSS PER SHARE $0.44.AT JUNE 30, 2019, CORVUS HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALING $96.8 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.43 -- REFINITIV IBES DATA.  Full Article

Novo Holdings A/S Cuts Share Stake In Corvus Pharmaceuticals Inc To 9.98% As Of July 29, 2019 From A Stake Of 15.1% As Of Jan 28, 2019
Tuesday, 30 Jul 2019 

July 29 (Reuters) - Corvus Pharmaceuticals Inc ::NOVO HOLDINGS A/S CUTS SHARE STAKE IN CORVUS PHARMACEUTICALS INC TO 9.98% AS OF JULY 29, 2019 FROM A STAKE OF 15.1% AS OF JAN 28, 2019 - SEC FILING.  Full Article

Corvus Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results
Friday, 8 Mar 2019 

March 7 (Reuters) - Corvus Pharmaceuticals Inc ::CORVUS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.CORVUS PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.36.CORVUS PHARMACEUTICALS - AS OF DEC 31, 2018, CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES TOTALING $114.6 MILLION COMPARED TO $90.1 MILLION AT DEC 31, 2017.CORVUS PHARMACEUTICALS INC - COMPANY EXPECTS NET CASH UTILIZATION OF $43 MILLION TO $47 MILLION IN 2019.  Full Article

Corvus Pharmaceuticals Announces Closing Of Public Offering Of Common Stock
Monday, 12 Mar 2018 

March 12 (Reuters) - Corvus Pharmaceuticals Inc ::CORVUS PHARMACEUTICALS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK.  Full Article

Corvus Pharmaceuticals reports third quarter 2017 financial results
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Corvus Pharmaceuticals Inc ::Corvus Pharmaceuticals reports third quarter 2017 financial results and clinical program update.Net loss for three months ended September 30, 2017, was $12.7 million compared to $10.3 million for same period in 2016​.  Full Article